卵巢组织冷冻与移植过程中卵巢储备损伤的前瞻性解决方案
本文综述卵巢组织冷冻保存及移植过程中卵巢储备受损的机制与对策,聚焦近5年研究,讨论慢速冷冻与玻璃化方案、移植部位与促血管新生、以及药物辅助治疗减少缺血损伤和抑制原始卵泡过度激活,指出虽已不再被视为实验性技术,仍需进一步研究以改善结局。
要点
- 卵巢组织冷冻是接受性腺毒性治疗患者恢复卵巢功能的唯一可用治疗。
- 移植组织易受缺血再灌注损伤和原始卵泡大量生长激活导致「耗竭」现象。
- 改进冻融方案、移植技术和药物辅助治疗是当前减少卵泡丢失的研究方向。
核心结论
- 卵巢组织冷冻及后续移植虽已被美国生殖医学学会指定为「不再属于实验性」,但仍需进一步研究以更好理解卵巢储备损伤来源并改善结局。
研究设计与样本
- 本文为文献综述,重点纳入近5年的新兴研究。
主要发现
- 移植组织高度易受缺血再灌注损伤和大量原始卵泡生长激活,导致「耗竭」现象。
- 冻融方案方面讨论了广泛接受的慢速冷冻方法和较新的玻璃化方案。
- 移植技术方面讨论了卵巢组织移植位置及移植部位促进新生血管形成的重要性。
- 药物辅助治疗方面有大量研究探讨减少缺血损伤、改善新生血管形成和抑制原始卵泡生长激活过度活跃的佐剂效果。
临床怎么用
- 卵巢组织冷冻是接受性腺毒性治疗患者恢复卵巢功能的唯一可用治疗,可恢复原生内分泌功能并支持妊娠和活产可能。
局限性
- 原文指出虽有「实验性」标签已被移除,但仍需进一步研究以更好理解卵巢储备损伤来源并改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Birth rates continue to decline as more women experience fertility issues. Assisted reproductive technologies are available for patients seeking fertility treatment, including cryopreservation techniques. Cryopreservation can be performed on gametes, embryos, or gonadal tissue and can be used for patients who desire to delay in vitro fertilization treatment. This review focuses on ovarian tissue cryopreservation, the freezing of ovarian cortex containing immature follicles. Ovarian tissue cryopreservation is the only available treatment for the restoration of ovarian function in patients who undergo gonadotoxic treatments, and its wide adoption has led to its recent designation as "no longer experimental" by the American Society for Reproductive Medicine. Ovarian tissue cryopreservation and subsequent transplantation can restore native endocrine function and can support the possibility of pregnancy and live birth for the patient. Importantly, there are multiple steps in the procedure that put the ovarian reserve at risk of damage. The graft is highly susceptible to ischemic reperfusion injury and mass primordial follicle growth activation, resulting in a "burnout" phenomenon. In this review, we summarize current efforts to combat the loss of primordial follicles in grafts through improvements in freeze and thaw protocols, transplantation techniques, and pharmacologic adjuvant treatments. We conducted a review of the literature, with emphasis on emergent research in the last 5 years. Regarding freeze and thaw protocols, we discuss the widely accepted slow freezing approach and newer vitrification protocols. Discussion of improved transplantation techniques includes consideration of the transplantation location of the ovarian tissue and the importance of graft sites in promoting neovascularization. Finally, we discuss pharmacologic treatments being studied to improve tissue performance postgraft. Of note, there is significant research into the efficacy of adjuvants used to reduce ischemic injury, improve neovascularization, and inhibit hyperactivation of primordial follicle growth activations. Although the "experimental" label has been removed from ovarian tissue cryopreservation and subsequent transplantation, there is a significant need for further research to better understand sources of ovarian reserve damage to improve outcomes. Future research directions are provided as we consider how to reach the most hopeful results for women globally.
引用
- Mercier A, Johnson J, Kallen AN, et al. Prospective solutions to ovarian reserve damage during the ovarian tissue cryopreservation and transplantation procedure. Fertil Steril. 2024. PMID: 39181229. doi:10.1016/j.fertnstert.2024.08.330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。